Genmab — Juni 2017
-
Novartis is also touting this week data showing its other CAR-T candidate, CTL119, when used with Janssen/Pharmacyclics’ Imbruvica (ibrutinib) produced complete responses in 8 out of 9 patients with CLL, also with no evidence of disease in their bone marrow at three months.
-
-
tror den får yderliger skub opad nu når usa åbner
-
mon GEN kan holde fast i sin C20 stilling? http://www.nasdaqomxnordic.com/digitalAssets/105/105663_nomxc_turnover21.pdf
-
Ja den kunne sagtens ende med en stigning på 4-5 % inden dagen er omme, nu hvor Citi kom med den flotte og positive analyse. Desuden er ASCO jo lige om hjørnet, og mon ikke der er nogle som gerne vil ind inden
-
Mine Genmab Bull*3 gør det os godt idag.
-
så er der ATH på gmxay - mon ikke vi ser et luk over 1450, hvis NBI kan holde flyvehøjden?
-
-
ja det ser forrygende ud.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind